On May 27, 2022 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022 (Press release, Bolt Biotherapeutics, MAY 27, 2022, View Source [SID1234618688]). The poster is titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data being presented at ASCO (Free ASCO Whitepaper) demonstrate that myeloid cells are consistently present in solid tumors. We believe this represents an attractive cellular target to address cancer more broadly. Myeloid cells are key cell types that serve as immunologic sentinels within the tumor microenvironment and can directly kill tumor cells or activate long-lasting cytotoxic T cells," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "Myeloid-targeted therapies, as single-agents or in combination with approved therapies, have the potential to benefit patients who may or may not have previously benefited from T cell-targeted approaches."
Bolt Biotherapeutics is currently developing a pipeline of myeloid-targeting therapies, including immune-stimulating antibody conjugates (ISACs) and BDC-3042 (a Dectin-2 agonistic antibody), designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells. Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types. The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration. These findings support the potential for myeloid-directed therapies to activate the innate immune system as a bridge to adaptive immunity, including patient populations who have demonstrated resistance to T cell-mediated immune checkpoint blockade. The data also validate the tumor cell expression of tumor antigens HER2, CEA, and PD-L1, all of which are targets of Boltbody ISAC candidates.
The ASCO (Free ASCO Whitepaper) abstract and poster presentation can be found on the Bolt website under Events & Presentations. Details regarding the presentation are as follows.
Title: Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs)
Presented by: Jason Ptacek, Ph.D.
Poster Session: Developmental Therapeutics – Immunotherapy
Time: Sunday, June 5, 8:00 a.m. – 11:00 a.m. CDT
Abstract Number: 2557
Poster Number: 212